Name | LNK754 |
---|---|
Synonyms |
(2R,3R)-2,3-Dihydroxysuccinic acid - 6-[(4-chlorophenyl)(hydroxy)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-2(1H)-quinolinone (1:1)
Butanedioic acid, 2,3-dihydroxy-, (2R,3R)-, compd. with 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-2(1H)-quinolinone (1:1) |
Description | LNK754 is a farnesyltransferase inhibitor, used for the treatment of cancer and Alzheimer's disease. |
---|---|
Related Catalog | |
In Vivo | LNK-754 (0.9 mg/kg) significantly reduces α-synuclein plaques in a mouse model of PD, APP(SL), at 6 months of age for 3 months[1]. |
References |
[1]. Keith T Gagnon. HD Therapeutics-CHDI Fifth Annual Conference. IDrugs. 2010 Apr;13(4):219-23. |
Molecular Formula | C29H22ClN3O2 |
---|---|
Molecular Weight | 479.96 |
Storage condition | 2-8℃ |